NCT05268913 (READ RISK) is a clinical trial of MRI scan in Breast Cancer, sponsored by University of Aberdeen.

Who is sponsoring NCT05268913?

NCT05268913 is sponsored by University of Aberdeen.

What drugs are being tested in NCT05268913?

Interventions in NCT05268913: MRI scan, Blood test.

What condition does NCT05268913 study?

NCT05268913 studies Breast Cancer.

Is NCT05268913 still recruiting?

NCT05268913 is currently status unknown. Last updated 7 March 2022.

Last reviewed 2022-03-07 · How we verify

NCT05268913: READ RISK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Towards Early Detection of Breast Cancer in High Risk Population

Status unknown Last updated 7 March 2022

What this trial tests

trial testing MRI scan in Breast Cancer in 120 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
1 May 2024

1 May 2024

Quick facts

Lead sponsor	University of Aberdeen
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 March 2022
Primary completion	1 May 2024
Estimated completion	1 May 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

MRI scan
Blood test — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

University of Aberdeen

Who can join

Adults 18 to 55, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breast cancer is a major and growing health challenge, and the leading cause of cancer in women. As population obesity rates increase, the number of new breast cancer diagnosis continues to rise. Despite treatment advances, breast cancer remains an important cause of premature mortality, taking women in the prime of life. Although underlying susceptibility caused by mutation in the genes including BRCA1/2 is increasingly identified, current pre-symptomatic screening for the general population and those at high genetic risk remains sub-optimal, with high false negative and positive rates. Alteration of breast lipid composition has been observed by us and others in patients with breast cancer and is thought to precede onset. We have developed and tested a novel method to allow a standard 3T MRI scanner to perform quantitative 3D mapping of specific lipid molecules in the breast. We will investigate if this method can detect very early breast cancers, and compare the amount and spread of lipid composition in breast tissue of premenopausal women with very high genetic risk of breast cancer, women with breast cancer and women with obesity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Contribution of n-3 Long-Chain Polyunsaturated Fatty Acids to the Prevention of Breast Cancer Risk Factors.
Fodil M, Blanckaert V, Ulmann L, Mimouni V, et al · · 2022 · cited 13× · PMID 35805595 · DOI 10.3390/ijerph19137936

Verify or expand the search:

Other trials of MRI scan

Trials testing the same drug.

NCT07384559 — Exploratory Study Investigating the Urinary Bladder During Intermittent Catheterization in Healthy and Spinal Cord Injur · NA · not yet recruiting
NCT04103372 — Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Sur · NA · recruiting
NCT06227182 — Magnetic Resonance Imaging and Ultrasound Comparison With Load Evaluation · recruiting
NCT06236048 — Energetics and Glutamate in Schizophrenia · recruiting
NCT06185478 — Prostate Diffusion Imaging With Distortion Correction · NA · suspended

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of Aberdeen trials

Trials by the same sponsor.

NCT07070765 — Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity · NA · not yet recruiting
NCT07065383 — Rebalancing the Fat Content of the Heart and Muscles · NA · recruiting
NCT06735573 — Protein, Sarcopenic Obesity, and COPD · not yet recruiting
NCT06714656 — Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young · NA · recruiting
NCT06721312 — Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relatio · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05268913 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aberdeen
Last refreshed: 7 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05268913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing